Literature DB >> 9792211

Mitochondria as cell targets of AZT (zidovudine).

M Barile1, D Valenti, E Quagliariello, S Passarella.   

Abstract

1. The subject of this review is the interaction between AZT (zidovudine) and mitochondria as described in papers dealing with AZT therapy both in AIDS patients and in model systems--that is, in cultured cells and in isolated mitochondria. 2. The structure and function of mitochondria are briefly described with discussion of the theoretical frame for a detailed bioenergetic investigation. 3. Experimental work is reported showing that mitochondria are cell AZT targets: changes in the structure and function induced by long-term AZT therapy as investigated both in AIDS patients and in model systems. 4. The AZT inhibition of energy-supplying reactions is considered in detail in studies dealing with long-term treatment and studies in which AZT was added to isolated mitochondria. In particular, adenylate kinase, ADP/ATP translocase and DNA polymerase gamma are reported as molecular targets of AZT. 5. Some perspectives of AZT therapy from the study of the effect of AZT on mitochondrion biochemistry are briefly reported.

Entities:  

Mesh:

Substances:

Year:  1998        PMID: 9792211     DOI: 10.1016/s0306-3623(98)00041-x

Source DB:  PubMed          Journal:  Gen Pharmacol        ISSN: 0306-3623


  11 in total

1.  Phosphorylation of thymidine and AZT in heart mitochondria: elucidation of a novel mechanism of AZT cardiotoxicity.

Authors:  Edward E McKee; Alice T Bentley; Matthew Hatch; Joel Gingerich; Delia Susan-Resiga
Journal:  Cardiovasc Toxicol       Date:  2004       Impact factor: 3.231

2.  Zidovudine inhibits thymidine phosphorylation in the isolated perfused rat heart.

Authors:  Delia Susan-Resiga; Alice T Bentley; Matthew D Lynx; Darcy D LaClair; Edward E McKee
Journal:  Antimicrob Agents Chemother       Date:  2007-01-12       Impact factor: 5.191

3.  3'-Azido-3'-deoxythymidine (AZT) is a competitive inhibitor of thymidine phosphorylation in isolated rat heart and liver mitochondria.

Authors:  Matthew D Lynx; Edward E McKee
Journal:  Biochem Pharmacol       Date:  2006-04-25       Impact factor: 5.858

Review 4.  Laboratory approach to mitochondrial diseases.

Authors:  D Parra; A González; C Mugueta; A Martínez; I Monreal
Journal:  J Physiol Biochem       Date:  2001-09       Impact factor: 4.158

5.  Site-specific reduction of oxidative and lipid metabolism in adipose tissue of 3'-azido-3'-deoxythymidine-treated rats.

Authors:  Catherine Deveaud; Bertrand Beauvoit; Annabel Reynaud; Jacques Bonnet
Journal:  Antimicrob Agents Chemother       Date:  2006-12-11       Impact factor: 5.191

6.  Combination exposure to zidovudine plus sulfamethoxazole-trimethoprim diminishes B-lymphocyte immune responses to Pneumocystis murina infection in healthy mice.

Authors:  David J Feola; Beth A Garvy
Journal:  Clin Vaccine Immunol       Date:  2006-02

7.  Mitochondrial disruption and apoptosis in lymphocytes of an HIV infected patient affected by lactic acidosis after treatment with highly active antiretroviral therapy.

Authors:  M Tolomeo; S Mancuso; M Todaro; G Stassi; M Catalano; S Arista; G Cannizzo; E Barbusca; V Abbadessa
Journal:  J Clin Pathol       Date:  2003-02       Impact factor: 3.411

8.  3'-Azido-3'-deoxythymidine (AZT) inhibits thymidine phosphorylation in isolated rat liver mitochondria: a possible mechanism of AZT hepatotoxicity.

Authors:  Matthew D Lynx; Alice T Bentley; Edward E McKee
Journal:  Biochem Pharmacol       Date:  2006-02-10       Impact factor: 5.858

9.  Myocarditis in CD8-depleted SIV-infected rhesus macaques after short-term dual therapy with nucleoside and nucleotide reverse transcriptase inhibitors.

Authors:  Lakshmanan Annamalai; Susan V Westmoreland; Heber G Domingues; Dennis G Walsh; R Gilberto Gonzalez; Shawn P O'Neil
Journal:  PLoS One       Date:  2010-12-23       Impact factor: 3.240

10.  Intracellular pharmacokinetic study of zidovudine and its phosphorylated metabolites.

Authors:  Lingli Mu; Rui Zhou; Fang Tang; Xingling Liu; Sanwang Li; Feifan Xie; Xiang Xie; Jie Peng; Peng Yu
Journal:  Acta Pharm Sin B       Date:  2015-12-21       Impact factor: 11.413

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.